Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Warren Fiskus

Showing results (51-60 of 94) with videos related to

Pageof 10
Sort By:
British Journal of Haematology|May 25, 2013
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosisDaniel J DeAngelo, Ruben A Mesa, Warren Fiskus, et al.
Blood|September 3, 2010
Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonistsAditya Mandawat, Warren Fiskus, Kathleen M Buckley, et al.
Blood|July 30, 2009
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cellsWarren Fiskus, Yongchao Wang, Arun Sreekumar, et al.
Blood|December 17, 2008
Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanismJianguang Chen, Warren Fiskus, Kelly Eaton, et al.
Blood|July 2, 2011
Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1Ramesh Balusu, Warren Fiskus, Rekha Rao, et al.
Leukemia|September 29, 2016
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cellsDyana T Saenz, Warren Fiskus, Taghi Manshouri, et al.
Blood|August 9, 2015
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinibBaohua Sun, Bhavin Shah, Warren Fiskus, et al.
Blood|October 16, 2009
Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cellsYongchao Wang, Warren Fiskus, Daniel G Chong, et al.
Cancer Research|March 7, 2014
Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemiaWarren Fiskus, Nakhle Saba, Min Shen, et al.
Molecular Cancer Therapeutics|January 18, 2014
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cellsWarren Fiskus, Sunil Sharma, Jun Qi, et al.
Pageof 10

Showing results (51-60 of 94) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|May 25, 2013
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosisDaniel J DeAngelo, Ruben A Mesa, Warren Fiskus, et al.
Blood|September 3, 2010
Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonistsAditya Mandawat, Warren Fiskus, Kathleen M Buckley, et al.
Blood|July 30, 2009
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cellsWarren Fiskus, Yongchao Wang, Arun Sreekumar, et al.
Blood|December 17, 2008
Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanismJianguang Chen, Warren Fiskus, Kelly Eaton, et al.
Blood|July 2, 2011
Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1Ramesh Balusu, Warren Fiskus, Rekha Rao, et al.
Leukemia|September 29, 2016
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cellsDyana T Saenz, Warren Fiskus, Taghi Manshouri, et al.
Blood|August 9, 2015
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinibBaohua Sun, Bhavin Shah, Warren Fiskus, et al.
Blood|October 16, 2009
Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cellsYongchao Wang, Warren Fiskus, Daniel G Chong, et al.
Cancer Research|March 7, 2014
Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemiaWarren Fiskus, Nakhle Saba, Min Shen, et al.
Molecular Cancer Therapeutics|January 18, 2014
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cellsWarren Fiskus, Sunil Sharma, Jun Qi, et al.
Pageof 10